Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation

References

• Verkouteren JAC, Ramdas KHR, Wakkee M, et al. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol. 2017;177(2):359–372. doi: 10.1111/bjd.15321
   PubMed Web of Science ®Google Scholar
• Basset-Seguin N, Herms F. Update in the management of basal cell carcinoma. Acta Derm Venereol. 2020; 100(11):adv00140. doi: 10.2340/00015555-3495
   PubMed Web of Science ®Google Scholar
• Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303–317. doi: 10.1016/j.jaad.2018.03.060
   PubMed Web of Science ®Google Scholar
• Kasumagic-Halilovic E, Hasic M, Ovcina-Kurtovic N. A Clinical Study of basal cell carcinoma. Med Arch (Sarajevo, Bosnia Herzegovina). 2019; 73(6):394–398. doi: 10.5455/medarh.2019.73.394-398
   PubMedGoogle Scholar
• Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: european consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34. doi: 10.1016/j.ejca.2019.06.003
   PubMed Web of Science ®Google Scholar
• Di Brizzi EV, Argenziano G, Brancaccio G, et al. The current clinical approach to difficult-to-treat basal cell carcinomas. Expert Rev Anticancer Ther. 2023;23(1):43–56. doi: 10.1080/14737140.2023.2161517
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic. Dermatol Ther. 2022;35(11): Published online August 2022:e15786. doi: 10.1111/dth.15786
   Web of Science ®Google Scholar
• Gutzmer R, Solomon JA. Hedgehog pathway inhibition for the treatment of basal cell carcinoma. Target Oncol. 2019; 14(3):253–267. doi: 10.1007/s11523-019-00648-2
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. New Emerging Treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164–1178. doi: 10.1007/s12325-022-02044-1
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Sonidegib: safety and efficacy in treatment of advanced basal cell carcinoma. Dermatol Ther (Heidelb). 2020;10(3):401–412. doi: 10.1007/s13555-020-00378-8
   PubMed Web of Science ®Google Scholar
• Sonidegib. EMA approval. cited Mar 31, 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdfLast
   Google Scholar
• Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 2013; 19(11):1410–1422. doi: 10.1038/nm.3389
   PubMed Web of Science ®Google Scholar
• Pak E, Segal RA. Hedgehog signal transduction: key players, oncogenic drivers, and cancer therapy. Dev Cell. 2016; 38(4):333–344. doi: 10.1016/j.devcel.2016.07.026
   PubMed Web of Science ®Google Scholar
• Rimkus TK, Carpenter RL, Qasem S, et al. Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel). 2016;8(2):22. doi: 10.3390/cancers8020022
   PubMed Web of Science ®Google Scholar
• Sanmartín O, Llombart B, Carretero Hernández G, et al. Sonidegib in the treatment of locally advanced basal cell carcinoma. Actas Dermosifiliogr. 2021;112(4):295–301. doi: 10.1016/j.ad.2020.11.002
   PubMed Web of Science ®Google Scholar
• Ramelyte E, Amann VC, Dummer R. Sonidegib for the treatment of advanced basal cell carcinoma. Expert Opin Pharmacother. 2016;17(14):1963–1968. doi: 10.1080/14656566.2016.1225725
   PubMed Web of Science ®Google Scholar
• Zollinger M, Lozac’h F, Hurh E, et al. Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(1):63–75. doi: 10.1007/s00280-014-2468-y
   PubMed Web of Science ®Google Scholar
• Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res An Off J Am Assoc Cancer Res. 2014;20(7):1900–1909. doi: 10.1158/1078-0432.CCR-13-1710
   PubMed Web of Science ®Google Scholar
• Pan S, Wu X, Jiang J, et al. Discovery of NVP-LDE225, a Potent and selective smoothened antagonist. ACS Med Chem Lett. 2010;1(3):130–134. doi: 10.1021/ml1000307
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020;34(9):1944–1956. doi: 10.1111/jdv.16230
   PubMed Web of Science ®Google Scholar
• Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res An Off J Am Assoc Cancer Res. 2011;17(8):2512–2520. doi: 10.1158/1078-0432.CCR-10-2736
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res An Off J Am Assoc Cancer Res. 2011;17(17):5774–5782. doi: 10.1158/1078-0432.CCR-11-0972
   PubMed Web of Science ®Google Scholar
• Odom D, Mladsi D, Purser M, et al. A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. J Skin Cancer. 2017;2017:6121760. doi: 10.1155/2017/6121760
   PubMedGoogle Scholar
• Goel V, Hurh E, Stein A, et al. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(4):745–755. doi: 10.1007/s00280-016-2982-1
   PubMed Web of Science ®Google Scholar
• Einolf HJ, Zhou J, Won C, et al. A Physiologically-Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients. Drug Metab Dispos. 2017;45(4):361–374. doi: 10.1124/dmd.116.073585
   PubMed Web of Science ®Google Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–728. doi: 10.1016/S1470-2045(15)70100-2
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369–1378. doi: 10.1111/bjd.18552
   PubMed Web of Science ®Google Scholar
• Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–381. doi: 10.1111/jdv.14542
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016;75(1):113–125.e5. doi: 10.1016/j.jaad.2016.02.1226
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Sonidegib efficacy and tolerability in advanced basal cell carcinoma: a single-center real-life experience. J Am Acad Dermatol. 2022;86(4):e175. doi: 10.1016/j.jaad.2021.11.041
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Scalvenzi M. Sonidegib treatment in patients with locally advanced basal cell carcinoma. Dermatol Ther. 2022;35(4):e15348. doi: 10.1111/dth.15348
   PubMed Web of Science ®Google Scholar
• Grossmann LE, Ramelyte E, Nägeli MC, et al. Eight years of real-life experience with smoothened inhibitors in a swiss tertiary skin referral center. Cancers (Basel). 2022;14(10):2496. doi: 10.3390/cancers14102496
   PubMed Web of Science ®Google Scholar
• Herms F, Baroudjian B, Delyon J, et al. Sonidegib in the treatment of locally advanced basal cell carcinoma: a retrospective study. Acta Derm Venereol. 2022;102:adv00740. doi: 10.2340/actadv.v102.1995
   PubMed Web of Science ®Google Scholar
• Toffoli L, Conforti C, Zelin E, et al. Locally advanced basal cell carcinoma: real-life data with sonidegib. Dermatol Ther. 2022;35(6):e15441. doi: 10.1111/dth.15441
   PubMed Web of Science ®Google Scholar
• Moscarella E, Brancaccio G, Briatico G, et al. Management of advanced basal cell carcinoma: real-life data with sonidegib. Dermatol Ther. 2021;34(3):e14948. doi: 10.1111/dth.14948
   PubMed Web of Science ®Google Scholar
• Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2022;21(1):21–29. doi: 10.1080/14740338.2022.1993819
   PubMed Web of Science ®Google Scholar
• Villani A, Scalvenzi M, Fabbrocini G, et al. Looking into a better future: novel therapies for metastatic melanoma. Dermatol Ther (Heidelb). 2021;11(3):751–767. doi: 10.1007/s13555-021-00525-9
   PubMed Web of Science ®Google Scholar
• Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: skin cancer-diagnosis, prevention, and treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291–297. doi: 10.1615/CritRevEukaryotGeneExpr.2020028454
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. The treatment of advanced melanoma: therapeutic update. Int J Mol Sci. 2022;23(12):6388. doi: 10.3390/ijms23126388
   PubMed Web of Science ®Google Scholar
• Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–179.
   PubMedGoogle Scholar
• Hernandez LE, Mohsin N, Levin N, et al. Basal cell carcinoma: an updated review of pathogenesis and treatment options. Dermatol Ther. 2022;35(6):e15501. doi: 10.1111/dth.15501
   PubMed Web of Science ®Google Scholar
• Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540–559. doi: 10.1016/j.jaad.2017.10.006
   PubMed Web of Science ®Google Scholar
• Villani A, Megna M, Fabbrocini G, et al. Long-term efficacy of vismodegib after its withdrawal and patients’ health-related quality of life using the dermatology life quality index (DLQI). Dermatol Ther (Heidelb). 2019;9(4):719–724. doi: 10.1007/s13555-019-00323-4
   PubMed Web of Science ®Google Scholar
• Leavitt E, Lask G, Martin S. Sonic hedgehog pathway inhibition in the treatment of advanced basal cell carcinoma. Curr Treat Options Oncol. 2019;20(11):84. doi: 10.1007/s11864-019-0683-9
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Expert opinion on sonidegib efficacy, safety and tolerability. Expert Opin Drug Saf. 2021;20(8):877–882. doi: 10.1080/14740338.2021.1921734
   PubMed Web of Science ®Google Scholar
• Alkeraye SS, Alhammad GA, Binkhonain FK. Vismodegib for basal cell carcinoma and beyond: what dermatologists need to know. Cutis. 2022;110(3):155–158. doi: 10.12788/cutis.0601
   PubMed Web of Science ®Google Scholar
• Scalvenzi M, Costa C, Cappello M, et al.; Reply to Woltsche N. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience. J Eur Acad Dermatol Venereol. 2019;33(4):e145–e147. doi: 10.1111/jdv.15469
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179. doi: 10.1056/NEJMoa1113713
   PubMed Web of Science ®Google Scholar
• Scalvenzi M, Villani A, Mazzella C, et al. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018;84(6):758–760. doi: 10.4103/ijdvl.IJDVL_92_18
   PubMed Web of Science ®Google Scholar
• Villani A, Scalvenzi M, Fabbrocini G, et al. Effects of COVID-19 pandemic on malignant melanoma diagnosis. J Eur Acad Dermatol Venereol. 2023;37(1):e22–e23. doi: 10.1111/jdv.18545
   PubMed Web of Science ®Google Scholar
• Trabelsi S, Khidher F. Rapid onset of response to sonidegib for multiple facial basal cell carcinomas during COVID-19 pandemic. Dermatol Ther. 2022;35(4):e15317. doi: 10.1111/dth.15317
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: management and adherence to treatment. J Am Acad Dermatol. 2020;82(6):e205. doi: 10.1016/j.jaad.2020.03.057
   PubMed Web of Science ®Google Scholar
• Villani A, Annunziata MC, Abategiovanni L, et al. Teledermatology for acne patients: how to reduce face-to-face visits during COVID-19 pandemic. J Cosmet Dermatol. 2020;19(8):1828. doi: 10.1111/jocd.13519
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, et al. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi: 10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, et al. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022; 21(6):2309–2310. doi: 10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Sonidegib with and without adjunctive treatment for locally advanced basal cell carcinomas. Oncology. 2022;27(6):e533.doi: 10.1093/oncolo/oyac063
   Google Scholar
• Gambini D, Passoni E, Nazzaro G, et al. Basal cell carcinoma and hedgehog pathway inhibitors: focus on immune response. Front Med. 2022;9:893063. doi: 10.3389/fmed.2022.893063
   Web of Science ®Google Scholar
• Fujii K, Miyashita T. Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review. Pediatr Int. 2014; 56(5):667–674. doi: 10.1111/ped.12461
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, et al. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22 (12):1431–1433. doi: 10.1080/14712598.2022.2113872
   PubMed Web of Science ®Google Scholar